Preeclampsia Diagnostics Market - Forecasts from 2024 to 2029

Preeclampsia Diagnostics Market - Forecasts from 2024 to 2029

The global preeclampsia diagnostics market is expected to grow at a CAGR of 2.60% from US$1.012 billion in 2022 to US$1.211 billion in 2029.

Preeclampsia is a hypertensive problem that creates complex problems in pregnant women by high levels of protein in urine indicating kidney damage. The growing prevalence of preeclampsia in pregnant women globally is creating a demand for diagnostic tests thereby boosting the preeclampsia diagnostics market. Moreover, the rising awareness about the risk factors from the complication coupled with government initiatives and technological advancements for enhanced prediction is further contemplated to boost the preeclampsia diagnostics market throughout the forecast period.Click here

Growing Prevalence of Preeclampsia Cases

The rising number of global preeclampsia cases due to irregular regulation of blood pressure is a major growth driver of the preeclampsia diagnostics market. According to National Institute of Health, around 50,000 maternal deaths and 500,000 fetal deaths occur each year worldwide due to preeclampsia complications. Moreover, hypertension occurs in 1 in every 12 – 17 pregnancies each year for women aged 20-44 years in the US as per the CDC estimates. High blood pressure is very common nowadays in pregnancy which is a defining feature of preeclampsia. Preeclampsia may create problems for women even after pregnancy showing the need for prevention and need for preeclampsia diagnostics tests thereby it is expected to drive the preeclampsia diagnostics market.

Multiple Risk Factors for Mother and Baby

There are various side effects of preeclampsia both on mother and baby and thus, it is required to treat the preeclampsia thereby it propels the preeclampsia diagnostics market. It may cause preterm births which increase breathing and feeding problems and in rare cases, it may result in maternal and infant health. Babies may suffer from Intrauterine Growth Restriction (IUGR) and various studies have shown that children born with IUGR are more prone to diabetes, congestive heart failure, and hypertension in their adult age. According to the Preeclampsia Foundation, around 15% of 30 million infants born each year are associated with preeclampsia.

Government and Other Institutions’ Awareness Program

The government programs to raise awareness about preeclampsia complications are driving the preeclampsia diagnostics market. The California Department of Public Health runs a communication campaign in May as a preeclampsia awareness month. Moreover, the Maternal, Child, and Adolescent Health (MCAH) division of the country created a social media presence to increase awareness about signs and symptoms of preeclampsia in several languages including Arabic, Chinese, English, Farsi, Korean, Spanish Tagalog, and Vietnamese. Additionally, the campaigns by various organizations are also expected to boost the preeclampsia diagnostics market. For instance, the Check Know Share campaign was launched by Preeclampsia Foundation in May 2020 to urge pregnant women to check their blood pressure, know and understand their numbers and share with their healthcare provider. This was also the theme of the preeclampsia awareness month of 2020.

Technological Advancements and Innovation

The technological advancements in the healthcare industry, enhancing the precision of preeclampsia test is boosting the preeclampsia diagnostics market. In March 2023, an innovative in-person placental growth factor test was introduced in North Wales which reduces stillbirths and pre-term deliveries. This test measures PLGF levels in just 15 minutes and enables quickly segmenting pregnant women by risk. Moreover, a new algorithm for predicting preeclampsia and tackling worsening mortality rates was announced by Ascertain and Caire Health (Joint Venture by Northwell Health and Aegis Ventures). Ascertain’s algorithm showed a 10-15% increase over current predictive standards. The company’s VC also said that preeclampsia is extremely addressable with machine learning.

Opportunities in the Market

The growing prevalence of hypertension in pregnant women provides a good opportunity for preeclampsia diagnostics market expansion. Moreover, investment prospects in the healthcare industry provide a major opportunity to enter the preeclampsia diagnostics market. For instance, Mirvie raised $60 million in series B funding for the development of breakthrough devices for preeclampsia tests. The Vision Grant Program by Preeclampsia Foundation provides financial help of up to $25,000 every year to study preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Further, the rising awareness among pregnant women due to various awareness programs and increased accessibility to diagnostic tests is also anticipated to propel the preeclampsia diagnostics market thereby providing an excellent opportunity for market expansion.

North America is an Expected Dominant Market

The North American region is expected to hold a significant share of the global preeclampsia diagnostics market during the forecasted period. Various factors attributed to such a share are rising preeclampsia complications in the region and rising awareness among women to adopt the preeclampsia diagnostics test. For instance, the prevalence rate of preeclampsia has increased by 25% in the last two decades in America as per the Preeclampsia Foundation. Moreover, the recent technological developments and presence of market leaders such as Quidel Corporation and Prestige Brands Holdings further enhance the scope of the preeclampsia diagnostics market in the region.

Preeclampsia Diagnostics Market Players
Atlas Medical, founded in 1996 is a supplier of quality diagnostic reagents and kits. The company provides HCG latex kits to detect major hormones in the fields of thyroid and fertility, and HCG test cassettes, individually pouched for pregnant women.
EKF Diagnostics Holdings PLC focuses on point-of-care testing, central laboratory tests, enzyme manufacturing, and the provision of contract manufacturing. The company offers a range of hemoglobin analyzers to identify women with gestational diabetes and help in managing their condition.

Key Market Development
In January 2024, LabCorp (NYSE: LH), a leading provider of advanced laboratory services worldwide, announced the release of a new blood test, cleared by the FDA, designed for assessing the risk and managing severe preeclampsia, a dangerous condition characterized by high blood pressure during pregnancy and after childbirth. Developed by Thermo Fisher Scientific and recognized as one of TIME Magazine's top inventions of 2023, this innovative test measures two specific angiogenic biomarkers linked to preeclampsia: serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF).
In May 2023, Thermo Fisher Scientific announced that it had received approval from the US Food and Drug Administration (FDA) for two assays designed to evaluate the risk of developing a severe pregnancy complication known as preeclampsia. The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) assays can be performed in just 30 minutes using the BRAHMS KRYPTOR chemistry analyzer. These assays are the first and only immunoassays to date to receive breakthrough designation and clearance from the FDA for assessing risk and assisting in the clinical management of preeclampsia, as stated by the company. Preeclampsia, a potentially life-threatening condition characterized by high blood pressure, is the leading cause of maternal and fetal mortality and morbidity globally. Incidence rates for this condition have been rapidly increasing in the United States.
In May 2022, Metabolomics Diagnostics entered into a partnership with Preeclampsia Foundation to improvise preeclampsia prediction by creating precise and less biased tests. Moreover, the partnership aims to improve maternal health by educating and preventing bad outcomes.
In June 2021, LifeCell launched screening for both early-onset and late-onset preeclampsia screening in India. The company became the first provider in India to offer screening for the early and late-onset. There is an addition of the Sflt-1 biomarker in the screening panel to help in accurate diagnosis even in the third trimester.

Segmentation:

By Test Type
Blood Test
Urine Test
Others
By Products & Services
Instruments
Reagents & Consumables
Services
By End-User
Hospitals
Diagnostic Centers
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others